SCHEMBL4351845

SCHEMBL4351845

O=C(Nc1ccc(O)cc1O)Nc1cccc2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 8/20 0.66
CXCR1 P25024 1/20 0.64
KDM4E B2RXH2 4/20 0.62
MAPT P10636 3/20 0.62
MEN1 O00255 3/20 0.62
RAB9A P51151 3/20 0.62
KMT2A Q03164 3/20 0.62
POLB P06746 2/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA9 Q16790 1/20 0.58
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
GAA P10253 1/20 0.55
CYP2C19 P33261 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
NPC1 O15118 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21861996 0.88 KDM4E (0.60) TRPV1KDM4EMAPTMEN1RAB9A
SCHEMBL6568502 0.85 RAB9A (0.68) TRPV1KDM4EMAPTMEN1RAB9A
SCHEMBL1276481 0.83 KDM4E (0.82) KDM4EMAPTMEN1RAB9AKMT2A
SCHEMBL30393282 0.83 KDM4E (0.82) KDM4EMAPTMEN1RAB9AKMT2A
SCHEMBL22588891 0.82 KDM4E (0.74) TRPV1KDM4EMAPTMEN1RAB9A
SCHEMBL21751022 0.81 KDM4E (0.79) TRPV1KDM4EMAPTMEN1RAB9A
SCHEMBL5595247 0.81 CXCR1 (0.69) TRPV1CXCR1KDM4EMAPTMEN1
SCHEMBL4347676 0.78 CXCR1 (0.68) CXCR1KDM4EMAPTMEN1RAB9A
SCHEMBL13151456 0.78 TRPV1 (1.00) TRPV1KDM4EMAPTMEN1RAB9A
SCHEMBL4350075 0.78 CXCR2 (0.71) TRPV1CXCR1KDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 TRPV1 2328/4885CXCR1 832/4885KDM4E 2662/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 TRPV1 2320/4885CXCR1 1199/4885KDM4E 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.